View in EDS HTML Full Text PDF Full Text

MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.

Saved in:
Bibliographic Details
Title: MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.
Authors: Guérin C; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France., Vinchent A; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France., Fernandes M; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France., Damour I; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France., Laratte A; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France., Tellier R; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France., Estevam GO; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA., Meneboo JP; Univ. Lille, Plateau de génomique fonctionnelle et structurale, CHU Lille, France., Villenet C; Univ. Lille, Plateau de génomique fonctionnelle et structurale, CHU Lille, France., Descarpentries C; Department of Biochemistry and Molecular Biology, Hormonology Metabolism Nutrition Oncology, CHU Lille, France., Fraser JS; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA., Figeac M; Univ. Lille, Plateau de génomique fonctionnelle et structurale, CHU Lille, France., Cortot AB; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.; Thoracic Oncology Department, Univ. Lille, CHU Lille, France., Rouleau E; Department of Medical Biology and Pathology, Cancer Genetics Laboratory, Gustave Roussy, Villejuif, France., Tulasne D; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.
Source: Molecular oncology [Mol Oncol] 2025 Aug; Vol. 19 (8), pp. 2366-2387. Date of Electronic Publication: 2025 Feb 20.
Publication Type: Journal Article
Journal Info: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39980226
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Guérin+C%22">Guérin C</searchLink>; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.<br /><searchLink fieldCode="AU" term="%22Vinchent+A%22">Vinchent A</searchLink>; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.<br /><searchLink fieldCode="AU" term="%22Fernandes+M%22">Fernandes M</searchLink>; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.<br /><searchLink fieldCode="AU" term="%22Damour+I%22">Damour I</searchLink>; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.<br /><searchLink fieldCode="AU" term="%22Laratte+A%22">Laratte A</searchLink>; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.<br /><searchLink fieldCode="AU" term="%22Tellier+R%22">Tellier R</searchLink>; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.<br /><searchLink fieldCode="AU" term="%22Estevam+GO%22">Estevam GO</searchLink>; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Meneboo+JP%22">Meneboo JP</searchLink>; Univ. Lille, Plateau de génomique fonctionnelle et structurale, CHU Lille, France.<br /><searchLink fieldCode="AU" term="%22Villenet+C%22">Villenet C</searchLink>; Univ. Lille, Plateau de génomique fonctionnelle et structurale, CHU Lille, France.<br /><searchLink fieldCode="AU" term="%22Descarpentries+C%22">Descarpentries C</searchLink>; Department of Biochemistry and Molecular Biology, Hormonology Metabolism Nutrition Oncology, CHU Lille, France.<br /><searchLink fieldCode="AU" term="%22Fraser+JS%22">Fraser JS</searchLink>; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Figeac+M%22">Figeac M</searchLink>; Univ. Lille, Plateau de génomique fonctionnelle et structurale, CHU Lille, France.<br /><searchLink fieldCode="AU" term="%22Cortot+AB%22">Cortot AB</searchLink>; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.; Thoracic Oncology Department, Univ. Lille, CHU Lille, France.<br /><searchLink fieldCode="AU" term="%22Rouleau+E%22">Rouleau E</searchLink>; Department of Medical Biology and Pathology, Cancer Genetics Laboratory, Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Tulasne+D%22">Tulasne D</searchLink>; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101308230%22">Molecular oncology</searchLink> [Mol Oncol] 2025 Aug; Vol. 19 (8), pp. 2366-2387. <i>Date of Electronic Publication: </i>2025 Feb 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22John+Wiley+%26+Sons%2C+Inc%22">John Wiley & Sons, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101308230 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1878-0261 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215747891%22">15747891 </searchLink><i>NLM ISO Abbreviation: </i>Mol Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39980226
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/1878-0261.13806
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2366
    Titles:
      – TitleFull: MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Guérin C
      – PersonEntity:
          Name:
            NameFull: Vinchent A
      – PersonEntity:
          Name:
            NameFull: Fernandes M
      – PersonEntity:
          Name:
            NameFull: Damour I
      – PersonEntity:
          Name:
            NameFull: Laratte A
      – PersonEntity:
          Name:
            NameFull: Tellier R
      – PersonEntity:
          Name:
            NameFull: Estevam GO
      – PersonEntity:
          Name:
            NameFull: Meneboo JP
      – PersonEntity:
          Name:
            NameFull: Villenet C
      – PersonEntity:
          Name:
            NameFull: Descarpentries C
      – PersonEntity:
          Name:
            NameFull: Fraser JS
      – PersonEntity:
          Name:
            NameFull: Figeac M
      – PersonEntity:
          Name:
            NameFull: Cortot AB
      – PersonEntity:
          Name:
            NameFull: Rouleau E
      – PersonEntity:
          Name:
            NameFull: Tulasne D
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2025 Aug
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1878-0261
          Numbering:
            – Type: volume
              Value: 19
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Molecular oncology
              Type: main
ResultId 1